4D Molecular Therapeutics, Inc. (FDMT) Insider Trading

Last 12 months

Insiders sold $5.39M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Dec 2020.

Net open-market

−$5.39M

0 buys · 19 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

Dec 2020

Dec 15, 2020

Get an email when FDMT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 16	Scott Bizily Chief Legal Officer	Sold10b5-1 plan	1,635	$12.84	$21k	16%	Form 4
Oct 5	David Kirn See Remarks	Sold10b5-1 plan 2 parts	58,333	$12.92 average	$754k	7.6%	Form 4
Sep 16	Scott Bizily Chief Legal Officer	Sold10b5-1 plan	1,635	$13.65	$22k	16%	Form 4
Sep 14	David Kirn See Remarks	Sold10b5-1 plan	58,333	$13.90	$811k	7.1%	Form 4
Sep 1	Scott Bizily Chief Legal Officer	Sold10b5-1 plan	584	$14.00	$8k	6.3%	Form 4
Aug 19	David Kirn See Remarks	Sold10b5-1 plan 2 parts	69,076	$15.76 average	$1.09M	7.7%	Form 4
Aug 13 – 17	Scott Bizily Chief Legal Officer	Sold10b5-1 plan 2 parts	3,270	$12.10 average	$40k	28%	Form 4
Aug 4	David Kirn See Remarks	Sold10b5-1 plan	26,842	$10.23	$275k	3.1%	Form 4
Aug 3	David Kirn See Remarks	Sold10b5-1 plan	12,415	$10.05	$125k	1.4%	Form 4
Jul 9 – 10	David Kirn See Remarks	Sold10b5-1 plan 3 parts	58,333	$12.64 average	$738k	6.2%	Form 4
Jun 30	Scott Bizily Chief Legal Officer	Sold10b5-1 plan	6,566	$14.00	$92k	43%	Form 4
Jun 23	Scott Bizily Chief Legal Officer	Sold10b5-1 plan	9,810	$12.00	$118k	53%	Form 4
Jun 22	David Kirn See Remarks	Sold10b5-1 plan	114,746	$10.47	$1.2M	11%	Form 4
Jun 1	David Kirn See Remarks	Sold10b5-1 plan	1,922	$10.02	$19k	0.2%	Form 4
Mar 20	Ashoo Gupta VP, Finance and Controller	SoldNo plan 2 parts	390	$8.61 average	$3k	0.8%	Form 4
Dec 20, 2025	Ashoo Gupta VP, Finance and Controller	SoldNo plan 2 parts	389	$8.68 average	$3k	0.8%	Form 4
Dec 16, 2025	Scott Bizily Chief Legal Officer	Sold10b5-1 plan	1,635	$10.90	$18k	31%	Form 4
Nov 17, 2025	Scott Bizily Chief Legal Officer	Sold10b5-1 plan	1,635	$10.59	$17k	31%	Form 4
Oct 24, 2025	Scott Bizily Chief Legal Officer	Sold10b5-1 plan	2,678	$12.00	$32k	43%	Form 4
Oct 16, 2025	Scott Bizily Chief Legal Officer	Sold10b5-1 plan	1,635	$10.17	$17k	24%	Form 4
Oct 9, 2025	Scott Bizily Chief Legal Officer	Sold10b5-1 plan	2,408	$10.00	$24k	32%	Form 4
Sep 23, 2025	Scott Bizily Chief Legal Officer	Sold10b5-1 plan	2,407	$8.00	$19k	24%	Form 4

Oct 1610b5-1 plan
Scott Bizily
Chief Legal Officer · sold 1,635 at $12.84
$21k
16% of stake
Oct 510b5-1 plan
David Kirn
See Remarks · sold 58,333 at avg $12.92
$754k
7.6% of stake
Sep 1610b5-1 plan
Scott Bizily
Chief Legal Officer · sold 1,635 at $13.65
$22k
16% of stake
Sep 1410b5-1 plan
David Kirn
See Remarks · sold 58,333 at $13.90
$811k
7.1% of stake
Sep 110b5-1 plan
Scott Bizily
Chief Legal Officer · sold 584 at $14.00
$8k
6.3% of stake
Aug 1910b5-1 plan
David Kirn
See Remarks · sold 69,076 at avg $15.76
$1.09M
7.7% of stake
Aug 13 – 1710b5-1 plan
Scott Bizily
Chief Legal Officer · sold 3,270 at avg $12.10
$40k
28% of stake
Aug 410b5-1 plan
David Kirn
See Remarks · sold 26,842 at $10.23
$275k
3.1% of stake
Aug 310b5-1 plan
David Kirn
See Remarks · sold 12,415 at $10.05
$125k
1.4% of stake
Jul 9 – 1010b5-1 plan
David Kirn
See Remarks · sold 58,333 at avg $12.64
$738k
6.2% of stake
Jun 3010b5-1 plan
Scott Bizily
Chief Legal Officer · sold 6,566 at $14.00
$92k
43% of stake
Jun 2310b5-1 plan
Scott Bizily
Chief Legal Officer · sold 9,810 at $12.00
$118k
53% of stake
Jun 2210b5-1 plan
David Kirn
See Remarks · sold 114,746 at $10.47
$1.2M
11% of stake
Jun 110b5-1 plan
David Kirn
See Remarks · sold 1,922 at $10.02
$19k
0.2% of stake
Mar 20No plan
Ashoo Gupta
VP, Finance and Controller · sold 390 at avg $8.61
$3k
0.8% of stake
Dec 20, 2025No plan
Ashoo Gupta
VP, Finance and Controller · sold 389 at avg $8.68
$3k
0.8% of stake
Dec 16, 202510b5-1 plan
Scott Bizily
Chief Legal Officer · sold 1,635 at $10.90
$18k
31% of stake
Nov 17, 202510b5-1 plan
Scott Bizily
Chief Legal Officer · sold 1,635 at $10.59
$17k
31% of stake
Oct 24, 202510b5-1 plan
Scott Bizily
Chief Legal Officer · sold 2,678 at $12.00
$32k
43% of stake
Oct 16, 202510b5-1 plan
Scott Bizily
Chief Legal Officer · sold 1,635 at $10.17
$17k
24% of stake
Oct 9, 202510b5-1 plan
Scott Bizily
Chief Legal Officer · sold 2,408 at $10.00
$24k
32% of stake
Sep 23, 202510b5-1 plan
Scott Bizily
Chief Legal Officer · sold 2,407 at $8.00
$19k
24% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch FDMT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Biological Products, (No Diagnostic Substances)

RGNXRegenxbio Inc.

PLXProtalix Biotherapeutics Inc.

KYMRKymera Therapeutics Inc.

IPSCCentury Therapeutics, Inc.

CGENCompugen Ltd.

AUTLAutolus Therapeutics plc

CSBRChampions Oncology, Inc.

FENCFennec Pharmaceuticals Inc.

Spot a number that looks wrong? Check it in FDMT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing FDMT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.